FOXO4-DRIPeptideSenolyticTherapy

Why It Matters

Senescent cells contribute to a wide array of age-related diseases, from osteoarthritis and fibrosis to neurodegeneration, collectively affecting hundreds of millions globally and driving significant healthcare costs. Mainstream use would mean fewer age-related chronic illnesses, allowing individuals to experience healthier, more active later lives, reducing the burden on caregivers and healthcare systems. Companies developing senolytics would gain immensely, while some traditional treatments for age-related diseases might see reduced demand. Key barriers include demonstrating long-term safety, avoiding unintended consequences of removing senescent cells, and scaling production. Early human trials could yield results within 3-5 years, with broader clinical applications potentially 10-15 years away. Companies like Unity Biotechnology and Oisín Biotechnologies are pioneering senolytic development, with significant interest from US and European biopharma. A second-order consequence could be a re-evaluation of diagnostic criteria for 'aging' itself, shifting from symptom management to proactive cellular health.